Lowenstein Sandler represented New Mountain Capital portfolio company Topix Pharmaceuticals, Inc. (Topix) in its acquisition of ClarityRx Clinical Skin Care, Inc. (CarlityRX).
New Mountain Capital is a New York-based investment firm managing private equity, public equity, and credit funds with over $20 billion in assets under management. Topix is an independent leader in skincare with a differentiated portfolio of clinically-proven products and brands sold across the medical and natural channels. It is the largest provider of premium, micro-branded and branded skincare products, partnering with over 3,000 physicians in the U.S. ClarityRx is the emerging leader in the professional spa-dispensed skincare market. The company provides leading, professional-grade skincare products by seamlessly pairing cutting-edge technology with potent natural ingredients.
This acquisition boosts Topix’s product offering and market share by adding ClarityRx’s highly differentiated, modern brand to the Topix portfolio. For over 35 years, Topix has worked with leading dermatologists in the United States, including the largest multi-office practices, to deliver results for their patients while also providing them with the tools to build their own businesses. Acquiring ClarityRx will enable Topix to bring the same customer-centric focus to the professional spa market.
Lowenstein Sandler served as legal counsel to New Mountain Capital and Topix. The Lowenstein team included Marita A. Makinen, David L. Goret, Michael Walutes, Matt Savare, Vanessa A. Ignacio, Anthony W. Raymundo, Megan Monson, Bryan Sterba, and Jacob D. Unger.
